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Abstracts / Biol Blood Marrow Transplant 21 (2015) S171eS184S178and level of supportive care given was signiﬁcantly higher in
patients with icterus than without (P ¼ 0.224) and P¼
0.0081) respectively. Total days for disease resolution in pa-
tients with icterus was 32 days compared to 16 days for those
without (p¼0.022). Nine of the patients with icterus received
speciﬁc treatment compared to only one in the anicteric
group. Seven cases were diagnosed with VOD by the Seattle
criteria at a median of day +15 post HSCT, but treatment was
delayed by 1-11 days for lack of hyperbilirubinemia, 2 of
these never developed hyperbilirubinemia; 4 of 7 cases died.
Overall 2 with anicteric and 12 cases with icteric VOD died.
Discussion: The Baltimore criteria appear to bemore stringent
and cases with anicteric VOD do not meet these diagnostic
criteria. This retrospective study describes the features of
anicteric VOD at a single center. Even if the patients met the
Seattle criteria, treatment was delayed for lack of hyper-
bilirubinemia or ﬂow reversal on hepatic ultrasound, neither of
which are required criteria. Patients with anicteric VOD had a
better outcome than those with hyperbilirubinemia, but our
study shows that there can be signiﬁcant morbidity and even
mortality associated with anicteric VOD. There seems to be a
poor understanding and awareness of anicteric VOD as a diag-
nosis.Earlierdisease recognitioncould lead tomorepromptand
aggressive treatment leading to improved outcomes.226
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Background: Gonadal failure is a major long-term health
and quality of life concern in survivors of HCT. While ovarian
dysfunction is nearly universal followingmyeloablative (MA)
conditioning, it is likely variable after reduced-intensity
conditioning (RIC) HCT where there are substantial differ-
ences in intensity. GnRH agonists, such as leuprolide, have
been shown to decrease the rate of ovarian failure in those
receiving conventional chemotherapy, but little is known
about leuprolide’s effectiveness in the HCT population. We
sought to determine the impact of leuprolide on ovarian
function in recipients of MA conditioning and evaluate the
incidence of ovarian failure in women undergoing RIC HCT.
Methods: Post-menarchal females <50 years of age who
were scheduled to undergo HCT were recruited for the study.
Adequate ovarian function, as deﬁned by a baseline FSH level
less than 40 and normal menstrual cycles, was required.
Those undergoing MA HCT were treated with leuprolide
(long-acting 11.25 mg IM once + short-acting 0.2 mg daily for
14 days) prior to conditioning. MA regimens were variable.
Those undergoing RIC HCT were observed with nointervention. RIC regimens generally included cyclophos-
phamide (50 mg/kg), ﬂudarabine (150-200 mg/kg) and TBI
(200-300 cGy). FSHwasmeasured at baseline, day 100,180, 1
year, and 2 years following transplant.
Results: A total of 19 women were included (9 in the inter-
vention armand10observation only). In the intervention arm
(age 17 to 45 years), 6 of the 7 evaluable patients had malig-
nancies and one had an inherited bone marrow failure syn-
drome (IBMFS). The observation arm (age 13 to 45 years)
included 6 patients with aplastic anemia, 1 with a hemoglo-
binopathy,1with ametabolic disorder,1with an IBMFS, and a
single patient with a malignancy. Two patients in the inter-
vention arm were not evaluable (one died 34 days following
HCT and the other was lost to follow-up). There were no
adverse events related to leuprolide therapy. Five out of the 7
intervention patients were heavily pretreated with chemo-
therapy for their malignant conditions prior to HCT. The
incidence of ovarian failure in women undergoing MA trans-
plant who received leuprolidewas 57% (4 out of 7 subjects) at
day +180 compared to historically reported rates of ovarian
failure of >90% after MA transplant. In RIC HCT, the ovarian
failure rate was 20% (2 out of 10 subjects).
Conclusions: Leuprolide is not only safe, but it appears to
have a substantial impact on ovarian function preservation
after MA conditioning. These results were found despite the
majority of these women having received signiﬁcant gona-
dotoxic chemotherapy prior to being referred for HCT. In
addition, early data demonstrate that RIC with cyclophos-
phamide, ﬂudarabine and low-dose TBI is associated with a
low risk of ovarian failure. Further studies are needed to
conﬁrm these exciting ﬁndings.227
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Introduction: The increased survival of hematological pa-
tients has required to widen the care of these patients, with
emphasis in factors related to quality of life and late mor-
tality. Among them, osteoporosis (OP) is a fundamental
problem. Patients undergoing hematopoietic cell trans-
plantation (HCT) are at great risk of OP, mainly due to pro-
longed exposure to chemotherapy, immunosuppresants and
the hypogonadism frequently associated to these treatments.
Despite this, there is lack of strong evidence on this matter
and HCT guidelines are not clear on this problem.
Objectives: To evaluate parameters related to bone health in
patients undergoing HCT. To measure the frequency and
severity of the alterations in this group of patients.
Patients and Methods: Observational and retrospective
analysis of patients undergoing HCTat the Catholic University
Hematology-Oncology Department. All patients undergoing
HCT were recommended to have determination of 25-OH
vitamin D, PTHi, Calcium, Phosphorus and bone densitometry
(DXA). We included all patients with the evaluation before
HCT (preHCT) and 1 year after HCT (postHCT). Statistical
analysis was performed by SPSS v.21 software.
Results: We obtained data from 20 patients preHCT and 22
patients postHCT.Main diagnosiswere acutemyeloid leukemia
(n¼13; 32%), multiple myeloma (n¼11; 26%), acute lympho-
blastic leukemia (n¼9; 21%) and Hodgkin’s Lymphoma (n¼5;
12%). Mean age was 40 years (range: 17-67) and 67% were
males. In the preHCTgroup, themedian25-OHvitaminD levels
